This site is intended only for healthcare professionals residing in Malaysia

Search

Menu

Close

Log Out Our medicinesTherapy AreaExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information
Home

Menu

Close

RTIs & Acute Otitis MediaUpper Respiratory Tract Infections (Upper RTIs)Acute Bacterial SinusitisPharyngitis/TonsillitisAcute Otitis MediaAcute Otitis MediaLower Respiratory Tract Infections (Lower RTIs)Community-Acquired PneumoniaAcute Bacterial Exacerbation of Chronic BronchitisSTIsSexually Transmitted Infections (STIs)Infections by Chlamydia trachomatisInfections by Neisseria gonorrhoeaeChancroid/Genital Ulcers MenSSTIsSkin and Soft-Tissue Infections (SSTIs)Uncomplicated Skin and Soft-Tissue InfectionsSafetySafetySafetyAdditional InformationAdditional InformationIndication and SusceptibilityFormulationsMode of ActionReconstitution of Powder for Oral Suspension for PediatricsPediatric AdministrationResourcesResourcesPrescribing InformationEventsMaterialsVideos

Additional Information  |  Indication and Susceptibility

Indication and SusceptibilityTherapeutic Indications1*

ZITHROMAX is indicated for the treatment of the following infections when known or likely to be due to one or more susceptible microorganisms:

Lower Respiratory Tract Infections Bronchitis Find out more LoadingLower Respiratory Tract Infections Community-Acquired Pneumonia Find out more LoadingUpper Respiratory Tract Infections Sinusitis Find out more LoadingUpper Respiratory Tract Infections Pharyngitis/Tonsillitis Find out more LoadingAcute Otitis Media Acute Otitis Media Find out more LoadingSkin and Soft-Tissue Infections Skin and Soft-Tissue Infections Find out more LoadingSexually Transmitted Infections Uncomplicated Genital Infections due to Chlamydia trachomatis Find out more LoadingSexually Transmitted Infections Uncomplicated Genital Infections due to Neisseria gonorrhoeae Find out more Loading* The full list of indications can be found in the local product document.

Considerations should be given to official guidance regarding the appropriate use of antibacterial agents.1

Susceptibility1

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

Antibacterial Spectrum of ZITHROMAX
Scroll left to view table
Commonly susceptible species
Aerobic and facultative gram-positive bacteria
Staphylococcus aureus
Streptococcus agalactiae*
Streptococcus pneumoniae*
Streptococcus pyogenes*
Other β-hemolytic streptococci (Groups C, F, G), and viridans streptococci
Aerobic and facultative gram-negative bacteria
Bordetella pertussis
Haemophilus ducreyi*
Haemophilus influenzae*
Haemophilus parainfluenzae*
Legionella pneumophila
Moraxella catarrhalis*
Neisseria gonorrhoeae*
Anaerobes
Clostridium perfringens
Peptostreptococcus spp.
Prevotella bivia
Other bacterial species
Borrelia burgdorferi
Chlamydia trachomatis
Chlamydophila pneumoniae*
Mycoplasma pneumoniae*
Treponema pallidum
Ureaplasma urealyticum
Species for which acquired resistance may be a problem
Aerobic and facultative gram-positive bacteria
Methicillin-resistant Staphylococcus aureus
Penicillin-resistant Streptococcus pneumoniae
Inherently resistant bacteria
Aerobic and facultative gram-negative bacteria
Pseudomonas spp.
Enterobacteriaceae
* The efficacy of ZITHROMAX against the indicated species have been demonstrated in clinical trialsOpportunistic Pathogens Associated With HIV Infection1

Eukaryotic microorganisms
Pneumocystis jirovecii and Toxoplasma gondii

Considerations should be given to official guidance regarding the appropriate use of antibacterial agents.1

TitleUse of ZITHROMAX should be undertaken with caution in patients with significant hepatic disease. Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death.1You might also be interested in...Resources ZITHROMAX® Mode of Action Watch now LoadingResources Pediatrics: How to Properly Administer ZITHROMAX® Watch now LoadingReference:Pfizer Malaysia ZITHROMAX Prescribing Information. Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=17705. Accessed January 2024.Additional Information ZITHROMAX® Safety Information Find out more Loading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for healthcare professionals residing in Malaysia. If you are a member of public wishing to access information on a specific medicine, please consult with your doctor.

 

This website is brought to you by
Pfizer (Malaysia) Sdn Bhd 197801003134
(40131-T)
Level 10 & 11, Wisma Averis (Tower 2),
Bangsar South, No. 8, Jalan Kerinchi, 
59200 Kuala Lumpur, Malaysia.
Tel: 603-2281 6000 
Fax: 603-2281 6388 
 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

PP-ZIT-MYS-0243-28FEB2024
You are now leaving the PfizerPro Malaysia website
​
You are now being directed to a third-party website. It is clarified that Pfizer will not be collecting, storing, or accessing any personal information shared by you on the third-party website and Pfizer's Privacy Policy will not apply. Pfizer does not review or control or endorse the content of the third-party website and shall have no liability / assumes no responsibility for any issues arising out of you accessing the third-party website, accuracy of the information, practices, and standards of the third-party website. You will be bound by the Privacy Policy and Terms of Use of the third-party website and be solely responsible for your interactions with that website.
 
     PP-UNP-MYS-0077 - 10FEB2023